Literature DB >> 16474405

Germline KRAS mutations cause Noonan syndrome.

Suzanne Schubbert1, Martin Zenker, Sara L Rowe, Silke Böll, Cornelia Klein, Gideon Bollag, Ineke van der Burgt, Luciana Musante, Vera Kalscheuer, Lars-Erik Wehner, Hoa Nguyen, Brian West, Kam Y J Zhang, Erik Sistermans, Anita Rauch, Charlotte M Niemeyer, Kevin Shannon, Christian P Kratz.   

Abstract

Noonan syndrome (MIM 163950) is characterized by short stature, facial dysmorphism and cardiac defects. Heterozygous mutations in PTPN11, which encodes SHP-2, cause approximately 50% of cases of Noonan syndrome. The SHP-2 phosphatase relays signals from activated receptor complexes to downstream effectors, including Ras. We discovered de novo germline KRAS mutations that introduce V14I, T58I or D153V amino acid substitutions in five individuals with Noonan syndrome and a P34R alteration in a individual with cardio-facio-cutaneous syndrome (MIM 115150), which has overlapping features with Noonan syndrome. Recombinant V14I and T58I K-Ras proteins show defective intrinsic GTP hydrolysis and impaired responsiveness to GTPase activating proteins, render primary hematopoietic progenitors hypersensitive to growth factors and deregulate signal transduction in a cell lineage-specific manner. These studies establish germline KRAS mutations as a cause of human disease and infer that the constellation of developmental abnormalities seen in Noonan syndrome spectrum is, in large part, due to hyperactive Ras.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474405     DOI: 10.1038/ng1748

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  237 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.

Authors:  Jin Xu; Christian Hedberg; Frank J Dekker; Qing Li; Kevin M Haigis; Eugene Hwang; Herbert Waldmann; Kevin Shannon
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

3.  Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Authors:  Leopold Groesser; Eva Herschberger; Arno Ruetten; Claudia Ruivenkamp; Enrico Lopriore; Markus Zutt; Thomas Langmann; Sebastian Singer; Laura Klingseisen; Wulf Schneider-Brachert; Agusti Toll; Francisco X Real; Michael Landthaler; Christian Hafner
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

4.  Regulation of RAS oncogenicity by acetylation.

Authors:  Moon Hee Yang; Seth Nickerson; Eric T Kim; Caroline Liot; Gaelle Laurent; Robert Spang; Mark R Philips; Yibing Shan; David E Shaw; Dafna Bar-Sagi; Marcia C Haigis; Kevin M Haigis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

5.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 6.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

Review 7.  Ras and Rap signaling in synaptic plasticity and mental disorders.

Authors:  Ruth L Stornetta; J Julius Zhu
Journal:  Neuroscientist       Date:  2010-04-29       Impact factor: 7.519

Review 8.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

9.  High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Authors:  Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross L Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc M Loriaux
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

10.  Genotype differences in cognitive functioning in Noonan syndrome.

Authors:  E I Pierpont; M E Pierpont; N J Mendelsohn; A E Roberts; E Tworog-Dube; M S Seidenberg
Journal:  Genes Brain Behav       Date:  2008-12-11       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.